ArticleToxicological sciences : an official journal of the Society of Toxicology2019
Placental BCRP/ABCG2 Transporter Prevents Fetal Exposure to the Estrogenic Mycotoxin Zearalenone.
Article in Toxicological sciences : an official journal of the Society of Toxicology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Investigating the role of food pollutants in autism spectrum disorder: a comprehensive analysis of heavy metals, pesticides, and mycotoxins.Naunyn-Schmiedeberg's archives of pharmacology · 2025Pooled it
- Pooled it
- Article
- ABCG2 Genetic Variability in Drug Exposure and Toxicity: Implications for Clinical Practice.Toxics · 2026Review
- Maternal organophosphate pesticide exposure in relation to birthweight: Modification by placenta transporter genotype.Placenta · 2025Article
- Mycoestrogen Exposure during Pregnancy: Impact of theEnvironmental health perspectives · 2025Article
- Article
- Transcriptomic comparison of in vitro models of the human placenta.bioRxiv : the preprint server for biology · 2024Article
- Placental BCRP transporter reduces cadmium accumulation and toxicity in immortalized human trophoblasts.Reproductive toxicology (Elmsford, N.Y.) · 2023Article
- A comparison of four liquid chromatography-mass spectrometry platforms for the analysis of zeranols in urine.Analytical and bioanalytical chemistry · 2023Article
- Article
- Protective role of the placental efflux transporter BCRP/ABCG2 in the relationship between prenatal cadmium exposure, placenta weight, and size at birth.Environmental research · 2023Article
- Regulation of Placental Efflux Transporters during Pregnancy Complications.Drug metabolism and disposition: the biological fate of chemicals · 2022Review
- Article
- BCRP/Drug metabolism and disposition: the biological fate of chemicals · 2021Article
- ZIKV Disrupts Placental Ultrastructure and Drug Transporter Expression in Mice.Frontiers in immunology · 2021Article
- Review of the environmental prenatal exposome and its relationship to maternal and fetal health.Reproductive toxicology (Elmsford, N.Y.) · 2020Review
- Breast cancer resistance protein (Bcrp/Abcg2) is selectively modulated by lipopolysaccharide (LPS) in the mouse yolk sac.Reproductive toxicology (Elmsford, N.Y.) · 2020Article
- Transporters in the Mammary Gland-Contribution to Presence of Nutrients and Drugs into Milk.Nutrients · 2019Review
- Developing novel in vitro methods for the risk assessment of developmental and placental toxicants in the environment.Toxicology and applied pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
In the placenta, the breast cancer resistance protein (BCRP)/ABCG2 efflux transporter limits the maternal-to-fetal transfer of drugs and chemicals. Previous research has pointed to the estrogenic mycotoxin zearalenone as a potential substrate for BCRP. Here, we sought to assess the role of the BCRP transporter in the transplacental disposition of zearalenone during pregnancy. In vitro transwell transport assays employing BCRP/Bcrp-transfected Madine-Darby canine kidney cells and BeWo trophoblasts with reduced BCRP expression were used to characterize the impact of BCRP on the bidirectional transport of zearalenone. In both models, the presence of BCRP protein increased the basolateral-to-apical transport and reduced the apical-to-basolateral transport of zearalenone over a 2-h period. In vivo pharmacokinetic analyses were then performed using pregnant wild-type and Bcrp-/- mice after a single tail vein injection of zearalenone. Zearalenone and its metabolite α-zearalenol were detectable in serum, placentas, and fetuses from all animals, and β-zearalenol was detected in serum and fetuses, but not placentas. There were no significant differences in the maternal serum concentrations of any analytes between the two genotypes. In Bcrp-/- mice, the free fetal concentrations of zearalenone, α-zearalenol, and β-zearalenol were increased by 115%, 84%, and 150%, respectively, when compared with wild-type mice. Concentrations of free zearalenone and α-zearalenol were elevated 145% and 78% in Bcrp-/- placentas, respectively, when compared with wild-type placentas. Taken together, these data indicate that the placental BCRP transporter functions to reduce the fetal accumulation of zearalenone, which may impact susceptibility to developmental toxicities associated with in utero zearalenone exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.